Additional components: magnesium stearate – 0,55 mg, corn starch – 19,895 mg, talc – 1,1 mg, monohydrate of lactose – 33 mg, colloid silicon dioxide – 0,275 mg.

Tablet cover: colloid silicon dioxide – 0,146 mg, sucrose – 22,459 mg, calcium carbonate – 3,006 mg, talc – 6,826 mg, titanium dioxide – 1,706 mg, a macrogoal of 6000 - 0,148 mg, коповидон – 0,592 mg, a karmelloza of sodium – 0,029 mg, povidone – 0,088 mg.

Indications to use

Contraception;
Syndrome of premenstrual tension;
Functional disturbances of a menstrual cycle, including a dysmenorrhea without the organic reason, a dysfunctional metrorrhagia.

Contraindications

Absolute:

Liver diseases in a heavy current;
Inborn hyperbilirubinemias (syndromes Cudgel Johnson, Gilbert, Rotor);
Arterial hypertension in severe forms;
Cholecystitis;
Vulval bleeding of unknown genesis;
Family forms of a lipidemia;
Heavy cerebrovascular / сердечно-сосудистые diseases (including existence of anamnestic data);
Malignant tumors (in particular endometrial cancer or mammary gland);
Migraine;
Thromboembolisms (existence and predisposition to their development);
Liver tumors;
Idiopathic jaundice of pregnant women in the anamnesis;
Endocrine diseases, including a diabetes mellitus in severe forms;
Hemolitic anemia in a chronic current;
Otosclerosis;
Heavy skin itch or herpes of pregnant women;
Sickemia;
Vesical drift;
Age of 40 years;
Pregnancy and period of a lactation;
Hypersensitivity to drug components.

Relative (Rigevidonum it is necessary to appoint with care in the presence of the following diseases / states):

Depression;
Tuberculosis;
Diabetes mellitus;
Diseases of a liver and gall bladder;
Mastopathy;
Multiple sclerosis;
Epilepsy;
Varicosity;
Diseases of kidneys;
Ulcer colitis;
Hidden tetany;
Phlebitis;
Otosclerosis;
Bronchial asthma;
Intermittent porphyria;
Diseases of cardiovascular system;
Hysterical chorea;
Hysteromyoma;
Arterial hypertension;
Functional disturbances of kidneys;
Teenage age (without regular ovulatory cycles).

Route of administration and dosage

Rigevidonum should be accepted inside, washing down with liquid in a small amount. It is not necessary to chew tablets.

Administration of drug needs to be begun from the first day of periods in cases if during the previous menstrual cycle hormonal contraception was not carried out.

Single dose – 1 tablet, course duration – 21 days (tablets from 1 packaging) then it is necessary to take a seven-day break. During this period there has to come menstrualnopodobny bleeding. Irrespective of, bleeding ended or not, for the eighth day it is necessary to resume reception of Rigevidonum from new packaging.

Upon transition to Rigevidonum from other peroral contraceptive means it is necessary to apply the similar scheme.

Duration of a course is defined by need for contraception.

It is recommended to begin reception of Rigevidonum after abortion in day of abortion or next day after carrying out operation.

It is contraindicated to the feeding women to accept Rigevidonum.

During the puerperal period not nursing women can only accept drug. It is recommended to begin therapy not earlier than the first day of periods.

The passed pill needs to be taken within the next few 12 hours. Decrease in contraceptive effect is observed in cases if the break between receptions of tablets made more than 36 hours. To avoid emergence of intermenstrual bloody allocations, reception of Rigevidonum needs to be continued from already begun packaging, excepting the passed tablet (i). In these cases use of additional, non-hormonal ways of contraception is recommended (for example, barrier).

The doctor sets the dosing mode at other indications (in the medical purposes) individually.

Side effects

In most cases Rigevidonum is transferred well.

During therapy development of the following spontaneously taking place side reactions of tranzitorny character is possible: nausea, headache, vomiting, nagrubaniye of mammary glands, acyclic bloody allocations, change of libido/weight/mood; in some cases – the century, a vision disorder, conjunctivitis, feeling of discomfort when carrying contact lenses swelled.

At long therapy development of a hloazma, decrease in hearing, a generalized itch, jaundice, increase in frequency of epileptic seizures, spasms of gastrocnemius muscles seldom or never can be observed.

Development of a hyperglycemia, gipertriglitseridemiya, jaundice, thromboses and venous thromboembolisms, skin rashes, candidiasis, diarrhea, fatigue, increase in arterial pressure, decrease in tolerance to glucose, changes of nature of vulval secretion was in rare instances noted.

Special instructions

Before purpose of Rigevidonum it is necessary to conduct the all-medical/gynecologic examination including assessment of a condition of mammary glands, control of arterial pressure, the cytologic analysis of a smear from a neck of uterus, the analysis of urine, definition of glucose in blood, cholesterol and other indicators of function of a liver. Further it is regularly necessary to conduct such examinations 1 time in half a year.

After the postponed viral hepatitis it is possible to apply Rigevidonum not earlier, than in 6 months after normalization of functions of a liver.

In cases of emergence of sharp hepatomegalias, pains in the upper parts of a stomach and symptoms indicating intraabdominal bleeding there can be a suspicion of a liver tumor (therapy cancellation is possible).

At functional disturbances of a liver against the background of reception of Rigevidonum it is necessary to consult at the specialist.

If there are acyclic (intermenstrual) bleedings, therapy needs to be continued as such bleedings, as a rule, spontaneously stop. If it does not occur, for an exception of organic pathology of reproductive system it is necessary to conduct medical examination.

Against the background of vomiting/diarrhea reception of Rigevidonum needs to be continued using other, non-hormonal contraceptive method.

At the smoking women administration of drug can promote increase in probability of developing of cardiovascular diseases with serious effects (a stroke, a myocardial infarction). The risk increases with age and quantity of the smoked cigarettes (in particular at women of 35 years).

Cancellation of therapy is required at emergence of the following states / diseases:

Acute deterioration in visual acuity;
Migrenepodobny headaches (development for the first time / strengthening);
Unusually severe headaches;
Precursory symptoms of phlebothrombosis/phlebitis (symptoms: unusual pains or swelling of veins standing);
Increase of epileptic seizures;
Cerebrovascular frustration;
Jaundice or hepatitis without jaundice;
The pricking pains of not clear genesis at cough/breath, pain and feeling of constraint in a thorax;
Generalized itch;
Suspicion of heart attack/thrombosis;
Sharp increase in arterial pressure.

Also reception of Rigevidonum should be cancelled at the occurred pregnancy and in 3 months prior to its planning, at a long immobilization and approximately in 1,5 months prior to the planned carrying out surgical intervention.

Medicinal interaction

At the combined use of Rigevidonum with some medicinal means / substances development of the following effects is possible:

Pyrazyl ketone derivatives, barbiturates, streptocides, some antiepileptic drugs (Phenytoinum, carbamazepine): strengthening of metabolism of the steroid hormones which are a part of Rigevidonum;
Some antimicrobic means (including Neomycinum, rifampicin, ampicillin, chloramphenicol, streptocides, polymyxin B, tetracyclines): reduction of contraceptive action (it is connected with intestinal microflora changes);
Tricyclic antidepressants, Maprotilinum, beta adrenoblockers: increase in their toxicity / bioavailability;
Anticoagulants derivative индандиона / coumarin: interaction development (additional definition of a prothrombin ratio and dose adjustment of anticoagulants can be appointed);
Peroral hypoglycemic drugs, insulin: correction of their mode of dosing can be required;
Drugs with a potential hepatotoxic action (for example, дантролен): strengthening of a hepatotoxic, in particular at women of 35 years;
Bromocriptinum: decrease in its efficiency.